TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
Objective. To evaluate the effectiveness and safety of TAS-102 monotherapy and combination therapy with bevacizumab in the treatment of metastatic colorectal cancer. Methods. The PubMed, Web of Science, MEDLINE, and Cochrane Library databases were searched for the literature on TAS-102 treatment of...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2021/4014601 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551612794535936 |
|---|---|
| author | Cheng-Jiang Liu Ting Hu Ping Shao Wu-Yang Chu Yu Cao Feng Zhang |
| author_facet | Cheng-Jiang Liu Ting Hu Ping Shao Wu-Yang Chu Yu Cao Feng Zhang |
| author_sort | Cheng-Jiang Liu |
| collection | DOAJ |
| description | Objective. To evaluate the effectiveness and safety of TAS-102 monotherapy and combination therapy with bevacizumab in the treatment of metastatic colorectal cancer. Methods. The PubMed, Web of Science, MEDLINE, and Cochrane Library databases were searched for the literature on TAS-102 treatment of metastatic colorectal cancer. Extracted data include median overall survival (mOS), median progression-free survival (mPFS), and the incidence of adverse events for meta-analysis. Results. Our study found that the mOS of patients treated with TAS-102 monotherapy was 6.95 (95% CI: 6.26-7.72) months and the mPFS was 2.53 (95% CI: 2.31-2.78) months. The mOS in patients treated by TAS-102 combined with bevacizumab was 10.41 (95% CI: 8.40-12.89) months, and the mPFS is 4.35 (95% CI: 3.05-6.20) months. In the control experiment, the patients’ mOS and mPFS were improved. TAS-102+B vs. TAS-102 (OR=0.41, 95% CI: 0.18-0.93; OR=0.72, 95% CI: 0.63-0.83) and TAS-102 vs. placebo (OR=0.44, 95% CI: 0.29-0.67; OR=0.51, 95% CI: 0.42-0.62) were studied to actively prevent the occurrence of neutropenia, leukopenia, febrile neutropenia, anemia, and vomiting. Conclusion. TAS-102 monotherapy and combination therapy with bevacizumab can significantly improve the survival of patients and prevent specific adverse events from happening. |
| format | Article |
| id | doaj-art-861a88753659480a8c0edd27582b8055 |
| institution | Kabale University |
| issn | 1687-630X |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-861a88753659480a8c0edd27582b80552025-02-03T06:01:00ZengWileyGastroenterology Research and Practice1687-630X2021-01-01202110.1155/2021/4014601TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal CancerCheng-Jiang Liu0Ting Hu1Ping Shao2Wu-Yang Chu3Yu Cao4Feng Zhang5Department of General MedicineDepartment of General PracticeDepartment of General MedicineDepartment of General MedicineDepartment of General MedicineDepartment of General SurgeryObjective. To evaluate the effectiveness and safety of TAS-102 monotherapy and combination therapy with bevacizumab in the treatment of metastatic colorectal cancer. Methods. The PubMed, Web of Science, MEDLINE, and Cochrane Library databases were searched for the literature on TAS-102 treatment of metastatic colorectal cancer. Extracted data include median overall survival (mOS), median progression-free survival (mPFS), and the incidence of adverse events for meta-analysis. Results. Our study found that the mOS of patients treated with TAS-102 monotherapy was 6.95 (95% CI: 6.26-7.72) months and the mPFS was 2.53 (95% CI: 2.31-2.78) months. The mOS in patients treated by TAS-102 combined with bevacizumab was 10.41 (95% CI: 8.40-12.89) months, and the mPFS is 4.35 (95% CI: 3.05-6.20) months. In the control experiment, the patients’ mOS and mPFS were improved. TAS-102+B vs. TAS-102 (OR=0.41, 95% CI: 0.18-0.93; OR=0.72, 95% CI: 0.63-0.83) and TAS-102 vs. placebo (OR=0.44, 95% CI: 0.29-0.67; OR=0.51, 95% CI: 0.42-0.62) were studied to actively prevent the occurrence of neutropenia, leukopenia, febrile neutropenia, anemia, and vomiting. Conclusion. TAS-102 monotherapy and combination therapy with bevacizumab can significantly improve the survival of patients and prevent specific adverse events from happening.http://dx.doi.org/10.1155/2021/4014601 |
| spellingShingle | Cheng-Jiang Liu Ting Hu Ping Shao Wu-Yang Chu Yu Cao Feng Zhang TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer Gastroenterology Research and Practice |
| title | TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer |
| title_full | TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer |
| title_fullStr | TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer |
| title_full_unstemmed | TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer |
| title_short | TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer |
| title_sort | tas 102 monotherapy and combination therapy with bevacizumab for metastatic colorectal cancer |
| url | http://dx.doi.org/10.1155/2021/4014601 |
| work_keys_str_mv | AT chengjiangliu tas102monotherapyandcombinationtherapywithbevacizumabformetastaticcolorectalcancer AT tinghu tas102monotherapyandcombinationtherapywithbevacizumabformetastaticcolorectalcancer AT pingshao tas102monotherapyandcombinationtherapywithbevacizumabformetastaticcolorectalcancer AT wuyangchu tas102monotherapyandcombinationtherapywithbevacizumabformetastaticcolorectalcancer AT yucao tas102monotherapyandcombinationtherapywithbevacizumabformetastaticcolorectalcancer AT fengzhang tas102monotherapyandcombinationtherapywithbevacizumabformetastaticcolorectalcancer |